# US 2010/0303826 A1 · Use of ADCC-Optimized antibodies for treating weak patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303826 A1
- Document ID: US20100303826A1
- Status: Published application
- Kind: A1
- Application number: 12/659,824
- Filed: 2010-03-23
- Published: 2010-12-02
- Earliest claimed: 2003-07-31
- Assignees: Lfb Biotechnologies
- Inventors: Dominique Bourel; Sylvie Jorieux; Christophe De Romeuf; Philippe Klein; Christine Gaucher; Nicolas Bihoreau; Emmanuel Nony
- Web page: https://patentgrep.com/patent/US20100303826A1

## CPC

- C07K 16/34: against blood group antigens
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- A61P 33/12: Schistosomicides
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/18: against material from animals or humans
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for treating conditions wherein the antigen is poorly expressed, comprising:
administering a composition of antibodies to a patient in need of,
wherein said antibodies are specific to the condition to be treated, and
wherein said antibodies are over 60%, for the forms G0+G1+G0F+G1F, given that the forms G0F+G1F are lower than 50%.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said patient is homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or said patient is heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F),

### Claim 18 (depends on 16)

The method according to claim 16, wherein the number of antigenic sites is below 250,000 per target cell.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the number of antigenic sites is below 100,000 per target cell.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the number of antigenic sites is below 50,000 per target cell.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the number of antigenic sites is below 5,000 per target cell.

### Claim 22 (depends on 16)

The method according to claim 16, wherein the dose of said antibody administered to the patient is between 2 and 100 times lower than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the dose of said antibody administered to the patient is between 5 and 25 times lower than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line.

### Claim 24 (depends on 16)

The method according to claim 16, wherein the antibody is directed against a non-ubiquitous antigen present in healthy donor cells, or an antigen of a pathological cell or of an organism pathogenic for humans.

### Claim 25 (depends on 16)

The method according to claim 16, wherein the antibody is selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CAl25, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, anti-CD44, and anti-viral antibodies.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the antibody is anti-HLA-DR.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the antibody is anti-CD20.
